Orvacabtagene autoleucel CAR T therapy induces IgM-dominant immunogenicity in 44.6% of patients, with minimal impact on T cell expansion.
Background
Chimeric Antigen Receptor (CAR) T cell therapies offer a promising approach for treating hematological malignancies like relapsed or refractory multiple myeloma (RRMM). However, a significant challenge is the potential for immunogenicity, where the patient's immune system develops antibodies against the CAR construct itself. These anti-CAR antibodies (ATAs) could theoretically compromise the therapy's efficacy by neutralizing CAR T cells, leading to reduced expansion or persistence and ultimately impacting patient outcomes. Understanding the nature and clinical relevance of this immune response is crucial for optimizing CAR T cell design and patient management.
Study Design
This study characterized the humoral immunogenicity of orvacabtagene autoleucel (orva-cel), a fully human BCMA-targeted CAR T cell therapy, in a phase 1/2 clinical study. Anti-CAR therapeutic domain-specific antibodies (ATAs) were monitored in 157 patients with RRMM over the course of the study. Comprehensive immune profiling, including isotype analysis (ELISA) and B cell epitope mapping, was performed to identify specific immunogenic regions within the CAR domain and characterize the antibody response. The impact of ATA status on CAR T cell expansion, persistence, and patient survival outcomes was also assessed.
Results
Anti-CAR therapeutic domain-specific antibodies (ATAs) were detected in 44.6% of the 157 treated patients, with both titers and incidence increasing over time. Immune profiling identified five immunodominant consensus peptide sequences within the CAR domain. These epitopes were targeted by both Immunoglobulin G (IgG) and Immunoglobulin M (IgM) isotypes, with a persistent IgM response observed in most ATA-positive individuals. Despite the presence of ATAs, no adverse impact on CAR T cell expansion was observed. However, reduced CAR T cell persistence was noted in ATA-positive patients. The authors suggest that the limited functional T- and B-cell capacity characteristic of relapsed or refractory multiple myeloma patients, potentially due to lymphodepletion and baseline immune suppression, may attenuate the clinical consequences of ATA development.
The analysis points to a weak, clinically non-relevant nature of the immune response, likely attributed to the patient's immune status and diseased state.
Key Findings
- Anti-CAR antibodies (ATAs) were detected in 44.6% of 157 orva-cel treated patients.
- The humoral response was characterized by both
IgGandIgMisotypes, with a persistentIgMcomponent. - Five immunodominant peptide sequences within the CAR domain were identified as targets for ATAs.
- ATA presence did not adversely affect CAR T cell expansion or patient survival outcomes.
- Reduced CAR T cell persistence was observed in ATA-positive patients, though without clinical impact.
Why It Matters
This study provides important reassurance for clinicians and patients regarding the immunogenicity of orvacabtagene autoleucel in relapsed or refractory multiple myeloma. Despite a high incidence of anti-CAR antibodies, the therapy's primary efficacy (CAR T cell expansion) remains largely unaffected. This suggests that the immune-compromised state of RRMM patients may mitigate the functional impact of these antibodies. While reduced persistence was observed, the lack of impact on expansion or survival outcomes implies that current CAR T cell protocols for RRMM may not need significant adjustments based on ATA development alone. Future CAR T designs could leverage the identified immunogenic hotspots to engineer less immunogenic constructs, potentially improving long-term persistence in patients with more robust immune systems.
orvacabtagene-autoleucel
car-t-cell-therapy
multiple-myeloma
immunogenicity
bcma
phase-1-2